Compare Chubb Ltd (CB) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chubb Ltd vs Citius Pharmaceuticals Inc — how do they compare? Chubb Ltd trades at $347.09 (market cap $134.37B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Chubb Ltd is far larger — about 7174.1× Citius Pharmaceuticals Inc's market cap, and Chubb Ltd pays a 1.17% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CB | CTXR | |
|---|---|---|
Market Cap | $134.37B | $18.73M |
Sector | Financials | Health |
52-Week High | $363.50 | $1.82 |
52-Week Low | $268.20 | $0.48 |
Enterprise Value | $155.22B | $14.95M |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chubb (CB) trades at $350.31, down 1.05% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals, with Q2 2026 EPS of $7.26 beating estimates, revenue growth to $59.78B in 2025, and a net income margin of 17.96%. Recent news highlights leadership appointments and positive earnings coverage.
The outlook is positive, supported by consistent earnings beats, a 52.38% analyst buy rating, and a consensus price target of $366.83. Risks include macroeconomic sensitivity and competitive pressures in insurance. The stock presents a value opportunity with a P/E of 12.41 and robust cash flow trends.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
